Literature DB >> 16516091

Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy.

Iacopo Olivotto1, Franco Cecchi, Roberto Gistri, Roberto Lorenzoni, Giampaolo Chiriatti, Francesca Girolami, Francesca Torricelli, Paolo G Camici.   

Abstract

OBJECTIVES: This study sought to evaluate whether the entity of microvascular dysfunction, assessed by positron emission tomography (PET), predicts the long-term development of left ventricular (LV) remodeling and systolic dysfunction in hypertrophic cardiomyopathy (HCM).
BACKGROUND: A subgroup of patients with HCM developed LV dilation and systolic impairment. A causal role of coronary microvascular dysfunction has been suggested as the underlying pathophysiological mechanism.
METHODS: Fifty-one patients (New York Heart Association functional class I to II) were followed up for 8.1 +/- 2.1 years after measurement of resting and dipyridamole (Dip) myocardial blood flow (MBF). Left ventricular systolic dysfunction was defined as an ejection fraction (LVEF) <50%.
RESULTS: The Dip-MBF was blunted in HCM patients compared with a group of healthy control patients (1.50 +/- 0.69 ml/min/g vs. 2.71 +/- 0.94 ml/min/g; p < 0.001). At final evaluation, 11 patients (22%) had an LVEF <50%; in most (n = 7), systolic dysfunction was associated with a significant increase in LV cavity dimensions (>5 mm) during follow-up. These 11 patients showed lower Dip-MBF than the 40 with preserved LV function (1.04 +/- 0.38 ml/min/g vs. 1.63 +/- 0.71 ml/min/g, respectively; p = 0.001); Dip-MBF was particularly blunted in five patients with clinical progression to severe heart failure symptoms or death (Dip-MBF 0.89 +/- 0.15 ml/min/g). At multivariate analysis, the two independent predictors of systolic dysfunction were Dip-MBF in the lowest tertile (<1.1 ml/min/g; relative hazard, 7.5; p = 0.038) and an end-diastolic LV dimension in the highest tertile (>45 mm; relative hazard, 12.3; p = 0.031).
CONCLUSIONS: Severe microvascular dysfunction is a potent long-term predictor of adverse LV remodeling and systolic dysfunction in HCM. Our findings indicate microvascular dysfunction as a potential target for prevention of disease progression and heart failure in HCM.

Entities:  

Mesh:

Year:  2006        PMID: 16516091     DOI: 10.1016/j.jacc.2005.10.050

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  59 in total

Review 1.  The clinical utility of assessing myocardial blood flow using positron emission tomography.

Authors:  Maria Cecilia Ziadi; Rob S B Beanlands
Journal:  J Nucl Cardiol       Date:  2010-08       Impact factor: 5.952

Review 2.  Clinical use of quantitative cardiac perfusion PET: rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM).

Authors:  Roberto Sciagrà; Alessandro Passeri; Jan Bucerius; Hein J Verberne; Riemer H J A Slart; Oliver Lindner; Alessia Gimelli; Fabien Hyafil; Denis Agostini; Christopher Übleis; Marcus Hacker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-05       Impact factor: 9.236

Review 3.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

4.  Coronary flow reserve in hypertrophic cardiomyopathy: relation with microvascular dysfunction and pathophysiological characteristics.

Authors:  M J Kofflard; M Michels; R Krams; M Kliffen; M L Geleijnse; F J Ten Cate; P W Serruys
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

5.  3.0 T magnetic resonance myocardial perfusion imaging for semi-quantitative evaluation of coronary microvascular dysfunction in hypertrophic cardiomyopathy.

Authors:  Liang Yin; Hai-Yan Xu; Sui-Sheng Zheng; Ying Zhu; Jiang-Xi Xiao; Wei Zhou; Si-Si Yu; Liang-Geng Gong
Journal:  Int J Cardiovasc Imaging       Date:  2017-06-13       Impact factor: 2.357

6.  Extent of late gadolinium enhancement at right ventricular insertion points in patients with hypertrophic cardiomyopathy: relation with diastolic dysfunction.

Authors:  Yinsu Zhu; Eun-Ah Park; Whal Lee; Hyung-Kwan Kim; Ajung Chu; Jin Wook Chung; Jae Hyung Park
Journal:  Eur Radiol       Date:  2015-01-18       Impact factor: 5.315

7.  Relationship between cardiac calcification and left ventricular hypertrophy in patients with chronic kidney disease at hemodialysis initiation.

Authors:  Ken Kitamura; Hideki Fujii; Kentaro Nakai; Keiji Kono; Shunsuke Goto; Tatsuya Nishii; Atsushi Kono; Shinichi Nishi
Journal:  Heart Vessels       Date:  2017-03-21       Impact factor: 2.037

Review 8.  Myocardial flow reserve (MFR) with positron emission tomography (PET)/computed tomography (CT): clinical impact in diagnosis and prognosis.

Authors:  Maria Cecilia Ziadi
Journal:  Cardiovasc Diagn Ther       Date:  2017-04

9.  Long-term prognostic value of coronary flow velocity reserve in patients with hypertrophic cardiomyopathy: 9-year follow-up results from SZEGED study.

Authors:  Attila Nemes; Erika Balázs; Osama I I Soliman; Róbert Sepp; Miklós Csanády; Tamás Forster
Journal:  Heart Vessels       Date:  2009-09-27       Impact factor: 2.037

10.  Monitoring of Cardiac Remodeling in a Mouse Model of Pressure-Overload Left Ventricular Hypertrophy with [18F]FDG MicroPET.

Authors:  Andrei Todica; Nick L Beetz; Lisa Günther; Mathias J Zacherl; Ulrich Grabmaier; Bruno Huber; Peter Bartenstein; Stefan Brunner; Sebastian Lehner
Journal:  Mol Imaging Biol       Date:  2018-04       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.